It would nevertheless be very interesting to define those subtypes in future research on BRAF/MEK and EGFR inhibition to confirm if screening for BM1 or BM2 at baseline could be used as predictive biomarker for sensitivity to targeted treatments in BRAFV600E mutant CRC. This evidence concerns the gene EGFR and colorectal carcinoma.